INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 3 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,553,168 | -64.8% | 29,817 | -57.2% | 0.04% | -63.1% |
| Q2 2023 | $4,415,557 | -24.7% | 69,734 | -35.6% | 0.10% | -40.5% |
| Q1 2023 | $5,867,369 | -64.1% | 108,354 | -64.9% | 0.17% | -62.5% |
| Q4 2022 | $16,333,546 | +8.5% | 308,646 | -4.6% | 0.46% | +4.1% |
| Q3 2022 | $15,058,000 | +4.1% | 323,609 | +27.7% | 0.44% | +9.4% |
| Q2 2022 | $14,459,000 | -2.1% | 253,319 | +5.0% | 0.40% | +16.0% |
| Q1 2022 | $14,762,000 | +37.7% | 241,255 | +17.8% | 0.35% | +54.4% |
| Q4 2021 | $10,720,000 | +192.3% | 204,822 | +108.2% | 0.23% | +175.6% |
| Q3 2021 | $3,667,000 | – | 98,356 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |